SpectraCure AB, Magistratsvägen 10, SE-226 43 Lund, Sweden.
J Biomed Opt. 2010 Sep-Oct;15(5):058003. doi: 10.1117/1.3495720.
The first results from a clinical study for Temoporfin-mediated photodynamic therapy (PDT) of low-grade (T1c) primary prostate cancer using online dosimetry are presented. Dosimetric feedback in real time was applied, for the first time to our knowledge, in interstitial photodynamic therapy. The dosimetry software IDOSE provided dose plans, including optical fiber positions and light doses based on 3-D tissue models generated from ultrasound images. Tissue optical property measurements were obtained using the same fibers used for light delivery. Measurements were taken before, during, and after the treatment session. On the basis of these real-time measured optical properties, the light-dose plan was recalculated. The aim of the treatment was to ablate the entire prostate while minimizing exposure to surrounding organs. The results indicate that online dosimetry based on real-time tissue optical property measurements enabled the light dose to be adapted and optimized. However, histopathological analysis of tissue biopsies taken six months post-PDT treatment showed there were still residual viable cancer cells present in the prostate tissue sections. The authors propose that the incomplete treatment of the prostate tissue could be due to a too low light threshold dose, which was set to 5 J∕cm2.
首次提出了应用在线剂量测定技术对低分级（T1c）原发性前列腺癌进行替莫泊芬介导的光动力疗法（PDT）的临床研究结果。据我们所知，这是首次在间质 PDT 中实时应用剂量测定反馈。IDOSE 剂量测定软件提供了剂量计划，包括基于从超声图像生成的 3D 组织模型的光纤位置和光剂量。使用用于输送光的相同光纤获得组织光学特性测量值。在治疗过程之前、期间和之后进行测量。根据这些实时测量的光学特性，重新计算光剂量计划。治疗的目的是在最小化对周围器官暴露的情况下消融整个前列腺。结果表明，基于实时组织光学特性测量的在线剂量测定能够使光剂量得到适应和优化。然而，在 PDT 治疗后 6 个月进行的组织活检的组织病理学分析显示，前列腺组织切片中仍存在有活性的癌细胞。作者提出，前列腺组织的不完全治疗可能是由于设定的 5 J∕cm2 太低的光阈值剂量所致。
